Emerald Health Therapeutics (OTC: EMHTF) is one of many cannabis related stocks that have been hard hit by sector volatility in 2019. After a rush to buy at the beginning of the year, most cannabis stocks have dropped. However, there’s still life in the industry, especially for investors who are willing to wait longer to see returns. Emerald Health Therapeutics stock trades at a bargain today, and the company shows promise with its focus on therapeutic treatments.
Many of the most popular mainstream cannabis stocks are pinned to growing companies that are focused on volume and return, rather than the inherent medicinal properties of marijuana. Emerald Health Therapeutics is different. This company researches and cultivates strains of Marijuana that show the most promise as medical treatments. While this is costly for the company now, it could result in better profits and better competitivity as the market matures.
Revenue growth has been strong for the company in recent years, but profitability is yet to be achieved. At the end of 2018, Emerald Health Therapeutics reported revenue growth of 107.80%. It generated $1.95 million CAD, its best ever result.
CBD products have been a major focus for the company, which should benefit the business as demand for these treatments increases. Stock is down -31.89% year to date, but the bargain pricing and the overall potential in the cannabis market make it an interesting pick for alternative investors.
- 1 Year Price Growth: -32.78%
- YTD Price Growth: -31.89%
- 3 Month Price Growth: -47.14%
All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.